Market Snapshot

BSE Sensex: 82944.31 0.54%
BSE 500: 36739.52 0.59%
BSE 200: 11626.92 0.66%
BSE 100: 26836.14 0.60%
BSE BANKEX: 68913.68 0.94%
BSE IT: 31118.86 -0.77%
Nifty 50: 25598 0.56%
Nifty 500: 23418.95 0.52%
Nifty 200: 14295.6 0.59%
Nifty 100: 26243.25 0.58%
Nifty Midcap 100: 59586.75 0.61%
Nifty Small 100: 17013.85 -0.04%
Nifty IT: 32039.5 -0.87%
Nifty PSU Bank: 9667.5 1.70%

News:

ASM Tech inks pact to acquire ...
Vikram Solar Ltd leads losers ...
Volumes soar at ABB India Ltd ...
Mason Infratech jumps on baggi...
Dee Development surges after b...

Cohance Lifesciences Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

20 Feb 2026 | 03:02 PM

305.60

-9.05 (-2.88%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Underperforms Index

-74.76%

Return (1Y)

Underperformed BSE Healthcare by 82.08%
More Volatile

2.48%

Standard Deviation (1Y)

Higher than BSE Healthcare by 1.6%
Inconsistent Performer

2/12

Months

underperformed BSE Healthcare
AxisDirect View

No View

52 Week High-Low

1,328

304

News & Announcements

Cohance Lifesciences consolidated net profit declines 76.01% in the December 2025 quarter
7 days ago

Cohance Lifesciences consolidated net profit declines 76.01% in the December 2025 quarter

13 - Feb - 2026 12:00 | 7 days ago

Net profit of Cohance Lifesciences declined 76.01% to Rs 36.72 crore in the quarter ended December 2025 as against Rs 153.07 crore during the previous quarter ended December 2024. Sales declined 19.47% to Rs 544.55 crore in the quarter ended December 2025 as against Rs 676.23 crore during the previous quarter ended December 2024.

Particulars Quarter Ended
Dec. 2025 Dec. 2024 % Var.

Sales 544.55 676.23 -19

OPM % 17.51 35.10 -

PBDT 92.40 248.13 -63

PBT 45.46 204.57 -78

NP 36.72 153.07 -76

Powered by Capital Market - Live News
Cohance Lifesciences receives warning letter from USFDA for its Hyderabad unit
13 days ago

Cohance Lifesciences receives warning letter from USFDA for its Hyderabad unit

07 - Feb - 2026 12:00 | 13 days ago

Cohance Lifesciences announced that the US FDA conducted an inspection at the Company's Finished Dosage Formulations manufacturing facility (FDF Unit-I) located at Nacharam, Hyderabad, from 04 August 2025 to 12 August 2025. Following the inspection, a Form FDA-483 containing six observations was issued by the US FDA. Based on these observations, the USFDA classified the facility as ?Official Action Indicated (OAI)? and subsequently issued a Warning Letter for the said facility.

The Company is required to respond to the Warning Letter within the stipulated timelines prescribed by the US FDA and continues to engage with the regulator thereafter.

The US revenues from this facility contributed less than 2% of consolidated revenues in FY25, with related EBITDA contribution below 1%.
Powered by Capital Market - Live News
Cohance Lifesciences receives warning letter for its Nacharam formulation facility
16 days ago

Cohance Lifesciences receives warning letter for its Nacharam formulation facility

04 - Feb - 2026 12:00 | 16 days ago

Pursuant to the USFDA inspection, Cohance Lifesciences has received a warning letter for the company's Nacharam formulation facility.
The Company had earlier informed the Stock Exchanges that the facility was classified as Official Action Indicated (OAI), and the said Warning Letter is in continuation of the same.
The inspection was conducted by the USFDA from 04 August 2025 to 12 August 2025.
Powered by Capital Market - Live News
Cohance Lifesciences to convene board meeting
52 days ago

Cohance Lifesciences to convene board meeting

30 - Dec - 2025 12:00 | 52 days ago

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 12 February 2026.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

Suven Pharmaceuticals Ltd is trading very close to its 52 Week Low
FII shareholding in Suven Pharmaceuticals Ltd has decreased by -7.56% since past 3 Months
MF shareholding in Suven Pharmaceuticals Ltd has increased by 5.28% since past 3 Months
FII shareholding in Suven Pharmaceuticals Ltd has decreased by -44.49% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Dec. 2025	Dec. 2024	% Var.
Sales	544.55	676.23	-19
OPM %	17.51	35.10	-
PBDT	92.40	248.13	-63
PBT	45.46	204.57	-78
NP	36.72	153.07	-76

General Notifications

My Notifications

Research Notifications

Cohance Lifesciences Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

305.60 -9.05 (-2.88%)

News & Announcements

Price vs Volume

Stock Trivia

Cohance Lifesciences Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

305.60

-9.05 (-2.88%)